Core Insights - The partnership between argenx and Monica Seles aims to raise awareness and understanding of myasthenia gravis (MG) through the 'Go for Greater' initiative at the 2025 U.S. Open Tennis Championships [1][2] - Seles publicly shares her experience with MG to empower patients and connect them with support resources [2] - Over 120,000 people in the U.S. are living with MG, which causes various symptoms including muscle weakness and fatigue [3] Company Overview - Argenx is a global immunology company focused on improving the lives of individuals suffering from severe autoimmune diseases [4] - The company collaborates with leading academic researchers through its Immunology Innovation Program to develop novel antibody-based medicines [4] - Argenx has developed the first approved neonatal Fc receptor (FcRn) blocker and is exploring its potential in multiple serious autoimmune diseases [4]